By Chris Wack

Innate Pharma shares were up 8% to $3.25 after Sanofi said that the U.S. Food and Drug Administration has granted Fast Track Designation for SAR'579/IPH6101 for the treatment of hematological malignancies.

Fast Track Designation is an FDA process designed to facilitate the development, and expedite the review of, medicines to treat serious conditions and fill unmet medical need.

SAR'579 is a trifunctional anti-CD123 cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

June 08, 2023 10:38 ET (14:38 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Innate Pharma (EU:IPH)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Innate Pharma
Grafico Azioni Innate Pharma (EU:IPH)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Innate Pharma